Bictegravir-Tenofovir alafenamide-Emtricitabine Biktarvy
Darunavir-Cobicistat-Tenofovir alafenamide-Emtricitabine Symtuza
Dolutegravir-Abacavir-Lamivudine Triumeq
Dolutegravir-Lamivudine Dovato
Dolutegravir-Rilpivirine Juluca
Doravirine-Tenofovir DF-Lamivudine Delstrigo
Efavirenz-Tenofovir DF-Emtricitabine Atripla
Elvitegravir-Cobicistat-Tenofovir alafenamide-Emtricitabine Genvoya
Elvitegravir-Cobicistat-Tenofovir DF-Emtricitabine Stribild
Rilpivirine-Tenofovir alafenamide-Emtricitabine Odefsey
Rilpivirine-Tenofovir DF-Emtricitabine Complera
Fostemsavir Rukobia
Ibalizumab Trogarzo
Maraviroc Selzentry
Dolutegravir Tivicay
Raltegravir Isentress
Tenofovir alafenamide-Emtricitabine Descovy
Tenofovir DF-Emtricitabine Truvada and Multiple Generics
Doravirine Pifeltro
Efavirenz Sustiva
Etravirine Intelence
Rilpivirine EdurantSelf-StudyCo-Occurring Conditions
You are just a few steps away from free CE credits!
Sign in or Register
A free account is required.
Study the Material
An entire Cc section, or just a few topics at a time.
Take the CE Quiz
5 questions covering the topics in each Cc section.
Claim CE Credit
Free CNE and Free CME available!
- Lesson 1 Overview
Latent Tuberculosis Infection - 0%Topic 1
BackgroundActivities- 0%Topic 2
Rationale and Indications for LTBI ScreeningActivities- 0%Topic 3
Methods Used to Test for Latent TuberculosisActivities- 0%Topic 4
Recommended LTBI Testing in Persons with HIVActivities- 0%Topic 5
Evaluation of Persons with a Positive LTBI Screening TestActivities- 0%Topic 6
Management of LTBI in Persons with HIVLatent Tuberculosis Infection Overview
About this Lesson
Last Updated: May 14th, 2025CNE/CME Continuing Education
This lesson qualifies for:- 1 CME AMA PRA Category 1 Credit™, or
- 1 CNE contact hour and 1 CE contact hour (does NOT qualify for pharmacology CE for advanced practice nurses)
CNE and CME Origination: October 1st, 2017CNE and CME Review: September 1st, 2023CNE and CME Expiration: August 31st, 2026 (3rd Edition)
View CE NoticesSteps to Acquire CE for this Lesson:
3Print CE Certificate
Obtain proof of CE3rd Edition
This is a substantial revision of the original Lesson. The previous edition was titled Latent Tuberculosis Infection and available until September 1st, 2023.Learning Objectives
- Discuss the epidemiology of tuberculosis and HIV coinfection in the United States
- State the rationale for screening for latent TB in people with HIV
- Describe and compare recommended screening tests for latent TB in people with HIV
- List recommended options for the treatment of latent TB in people with HIV
- Summarize common drug interactions between medications used to treat latent TB and common antiretroviral medications
Lesson Contributors
Authors
Sylvia M. LaCourse, MD, MPHSylvia M. LaCourse, MD, MPH
Assistant Professor, Medicine, Global Health, and Epidemiology (Adjunct)
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:Grant to Institution: MerckThe relevant financial relationship was mitigated.Aley G. Kalapila, MD, PhDAley G. Kalapila, MD, PhD
Professor of Medicine
Division of Infectious Diseases
Emory University School of Medicine
Grady Health SystemDisclosures:NoneReviewers
David H. Spach, MDDavid H. Spach, MD
Professor of Medicine
Division of Allergy & Infectious Diseases
University of WashingtonDisclosures:NoneLesson Plan
Quick Reference View
A single document for easy access to every topic in the self-study modules.
PDF version also available.
No sign-in required for Quick Reference
Question Bank
Interactive board-review style questions about Epidemiology of HIV.
CNE/CME CME+MOC credits and CNE contact hours available.
Requires sign-in for CE credit or Certificates
Funded byHealth Resources and Services Administration (HRSA)Created at University of WashingtonAn AETC ProgramPart of IDEA PlatformCME provided byUniversity of Alabama BirminghamCNE approved byOregon Nurses AssociationCopyright © 2025 National HIV CurriculumThe Health Resources and Services Administration (HRSA), Department of Health and Human Services (HHS) provided financial support for this website. The award provided 100% of total costs and totaled $1,172,994. The contents are those of the author. They may not reflect the policies of HRSA, HHS, or the U.S. Government.Since you've received 80% or better on this quiz, you may claim continuing education credit.
You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.
Current Version: nhivc-master-d52d2330-2025-09-05-201745 - 0%Topic 2